Barry E. Rosenbloom, MD
Moderator of the session, Barry E. Rosenbloom, MD, Clinical Professor of Medicine at Tower Hematology Oncology Medical Group in Los Angeles, said that the overview of recent advances in lung cancer clearly depicts oncology’s state of flux.
“There are so many different agents that have been approved for lung cancer,” said Dr. Rosenbloom. “The key moving forward will be building new algorithms of treatment to decide the proper order of agents based on molecular analyses.” ■
Disclosure: Dr. Rosenbloom reported no potential conflicts of interest.
With drug approvals for immunotherapy in the first- and second-line settings, breakthroughs in targeting epidermal growth factor receptor (EGFR) mutations, and the rapid evolution of therapies that target anaplastic lymphoma kinase (ALK) rearrangements, 2016 has been an extraordinary year for lung...